Barriers to Tofersen Therapy for Variant SOD1 -Mediated ALS

🔗 Access full article via JAMA Neurology

This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1-mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.